Latest Filings

Issuer Activity

Overview :: ACADIA Pharmaceuticals Inc. (OQ:ACAD) [?]
Business Focus: Biotechnology & Medical Research Share on StockTwits
Recent Price for ACAD
USD 19.44 0.00 (0.00%)
NSQ Delayed 15 minutes
Apr 17 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 32.00 N/A N/A 1,914.11
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 11.26 0.0% 2,522,599  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for ACAD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 6:55am ET April 21st, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 17/14 Apr 15/14 Hacksell Uli Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -25,000  
Apr 17/14 Apr 15/14 Hacksell Uli Indirect Ownership Common Stock S - Open market or private sale -25,000 $17.75
Apr 17/14 Apr 15/14 Hacksell Uli Indirect Ownership Common Stock G - Gift 25,000  
Apr 17/14 Apr 15/14 Hacksell Uli Direct Ownership Common Stock G - Gift -25,000  
Apr 17/14 Apr 15/14 Hacksell Uli Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 25,000 $6.95
Apr 4/14 Apr 4/14 Brege Laura Direct Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -14,285  
Apr 4/14 Apr 4/14 Brege Laura Direct Ownership Common Stock S - Open market or private sale -14,285 $22.54
Apr 4/14 Apr 4/14 Brege Laura Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 14,285 $1.75
Apr 4/14 Apr 4/14 Rasmussen Torsten Indirect Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -15,500  
Apr 4/14 Apr 4/14 Rasmussen Torsten Indirect Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -10,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for ACAD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 6:55am ET April 21st, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Apr 17/14 Apr 15/14 Hacksell Uli Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -25,000  
Apr 17/14 Apr 15/14 Hacksell Uli Indirect Ownership Common Stock S - Open market or private sale -25,000 $17.75
Apr 17/14 Apr 15/14 Hacksell Uli Indirect Ownership Common Stock G - Gift 25,000  
Apr 17/14 Apr 15/14 Hacksell Uli Direct Ownership Common Stock G - Gift -25,000  
Apr 17/14 Apr 15/14 Hacksell Uli Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 25,000 $6.95
Apr 4/14 Apr 4/14 Brege Laura Direct Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -14,285  
Apr 4/14 Apr 4/14 Brege Laura Direct Ownership Common Stock S - Open market or private sale -14,285 $22.54
Apr 4/14 Apr 4/14 Brege Laura Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 14,285 $1.75
Apr 4/14 Apr 4/14 Rasmussen Torsten Indirect Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -15,500  
Apr 4/14 Apr 4/14 Rasmussen Torsten Indirect Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -10,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Key People
Leslie L. Iversen
Independent Chairman of the Board
Uli Hacksell
President, Chief Executive Officer, Director
Thomas H. Aasen
Chief Financial Officer, Chief Business Officer, Executive Vice President, Treasurer
Roger M. Mills
Executive Vice President - Development, Chief Medical Officer
Terrence O. Moore
Executive Vice President, Chief Commercial Officer
Glenn F. Baity
Vice President, General Counsel, Secretary
Company Contact
Address: SUITE 100, 11085 TORREYANA ROAD
SAN DIEGO CA 92121
Tel: 1-858-5582871
Website: www.acadia-pharm.com
IR: ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Business Overview
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc., and a product candidate in Phase I development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.
Financial Overview
For the fiscal year ended 31 December 2013, ACADIA Pharmaceuticals Inc. revenues decreased 77% to $1.1M. Net loss increased 82% to $37.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other Research and Development EXP increase of 35% to $24.5M (expense), Other general and Administrative Expense increase of 60% to $9.2M (expense).
Employees: 48 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $1,728M as of Dec 31, 2013
Annual revenue (TTM): $1.15M as of Dec 31, 2013
EBITDA (TTM): -$38.22M as of Dec 31, 2013
Net annual income (TTM): -$37.95M as of Dec 31, 2013
Free cash flow (TTM): -$32.32M as of Dec 31, 2013
Net Debt Last Fiscal Year: N/A
Shares outstanding: 98,462,618 as of Mar 18, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Quintiles Transnational H (N:Q)
Incyte (OQ:INCY)
United Therapeutics (OQ:UTHR)